MedTrace Logo

Lerisetron Compared With Granisetron in Preventing Nausea and Vomiting in Men Being Treated With Radiation Therapy for Stage I Seminoma

NCT00004219 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2013-08-02

No results posted yet for this study

Summary

RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients treated with radiation therapy. It is not yet known whether lerisetron is more effective than granisetron in preventing nausea and vomiting.

PURPOSE: Randomized phase III trial to compare the effectiveness of lerisetron with that of granisetron in preventing nausea and vomiting in men who are being treated with radiation therapy for stage I seminoma.

Conditions

  • Nausea and Vomiting
  • Testicular Germ Cell Tumor

Interventions

DRUG

granisetron hydrochloride

DRUG

lerisetron

RADIATION

radiation therapy

Sponsors & Collaborators

  • Simbec Research

    lead INDUSTRY

Principal Investigators

  • David P. Dearnaley, MD, FRCP, FRCR · Royal Marsden NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004219 on ClinicalTrials.gov